Protocol Ledger

NCT05993325 · Phase III · ACTIVE NOT RECRUITING

Immunogenicity and Safety of AdCLD-CoV19-1 OMI As a Booster: a COVID-19 Preventive Vaccine in Healthy Volunteers

Interventional Phase III clinical trial protocol NCT05993325 sponsored by Cellid Co in Infectious Disease and Vaccines, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2023-11-27 Enrollment: 4,000 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT05993325
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)4,000 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05993325
Protocol FieldVerified Registry Value
NCT IdentifierNCT05993325
Consolidated Lead SponsorCellid Co
Therapeutic Condition CohortInfectious Disease and Vaccines
Clinical Trial PhasePhase III
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment4,000 participants (ESTIMATED)
Registered Start Date2023-11-27
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT05993325
Hospital Research SiteLocationSite Profile
Dong-A University HospitalBusan, South KoreaOpen Hospital Dossier ->
Kyungpook National University HospitalDaegu, South KoreaOpen Hospital Dossier ->
Chungnam National University HospitalDaejeon, South KoreaOpen Hospital Dossier ->
Chonnam National University HospitalGwangju, South KoreaOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Infectious Disease and Vaccines Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI